

# **Europe Veterinary Pain Management Market - Industry Trends and Forecast to 2032**

Market Report | 2023-09-01 | 252 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

## Report description:

Europe veterinary pain management market is expected to reach USD 779,744.79 thousand by 2030 from USD 535,409.78 thousand in 2022 growing at a CAGR of 5.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Market Segmentation

Europe Veterinary Pain Management Market, By Product Type (Analgesics, Corticosteroids, and Alpha 2 Agonists), Drug Type (Branded and Generic), Mode of Purchase (Prescription Based and OTC), Animal Type (Companion Animal and Production Animal), Pain Source (Chronic Pain, Acute Pain, Post-Operative Pain, and Dental Pain), Dosage (Solid, Liquid, and Semi-Solid), Route of Administration (Parenteral, Oral, and Topical), End User (Veterinary Hospitals, Veterinary Clinics, Pet Shops, Animal Farms, Academic & Research Institutes, and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Poland, Denmark, Sweden, Norway, Funland, and rest of Europe) - Industry Trends and Forecast to 2030 Overview of Europe Veterinary Pain Management Market Dynamics

#### Driver

- Rising incidences of pet diseases

#### Restraint

- High costs of pet care

### Opportunity

- Technological advancements for pain management

Market Players

Some of the major market players operating in the Europe veterinary pain management market are listed below:

Scotts International. EU Vat number: PL 6772247784

- Dechra Pharmaceuticals PLC
- Virbac
- Norbrook
- Durvet Animal Health Products
- Bimeda, Inc.
- Inovet ( A subsidiary of Orion Group)
- Chanelle Pharma
- Vetoquinol
- Elanco
- Merck & Co., Inc.
- Zoetis Services LLC
- Ceva Animal Health, LLC

### **Table of Contents:**

TABLE OF CONTENTS

- 1 INTRODUCTION 29
- 1.1 OBJECTIVES OF THE STUDY 29
- 1.2 MARKET DEFINITION 29
- 1.3 OVERVIEW OF THE EUROPE VETERINARY PAIN MANAGEMENT MARKET 29
- 1.4 CURRENCY AND PRICING 31
- 1.5 LIMITATIONS 31
- 1.6 MARKETS COVERED 32
- 2 MARKET SEGMENTATION 35
- 2.1 MARKETS COVERED 35
- 2.2 GEOGRAPHICAL SCOPE 36
- 2.3 YEARS CONSIDERED FOR THE STUDY 37
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 38
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
- 2.6 MULTIVARIATE MODELLING 42
- 2.7 MARKET END USER COVERAGE GRID 42
- 2.8 PRODUCT LIFELINE CURVE 43
- 2.9 DBMR MARKET POSITION GRID 44
- 2.10 VENDOR SHARE ANALYSIS 45
- 2.11 SECONDARY SOURCES 46
- 2.12 ASSUMPTIONS 46
- 3 EXECUTIVE SUMMARY 47
- 4 PREMIUM INSIGHTS 50
- 4.1 PESTEL ANALYSIS 51
- 4.2 PORTER'S FIVE FORCES 52
- 4.3 BRAND REVENUE ANALYSIS 53
- 5 MARKET OVERVIEW 54
- **5.1 DRIVERS 56**
- 5.1.1 INCREASING PET OWNERSHIP 56

Scotts International. EU Vat number: PL 6772247784

- 5.1.2 ADVANCEMENTS IN VETERINARY MEDICINE 56
- 5.1.3 GROWING INCIDENCES OF PET DISEASES 57
- 5.1.4 INCREASED GOVERNMENT PROJECTS TO ENHANCE ANIMAL CARE 57
- 5.2 RESTRAINTS 58
- 5.2.1 INCREASING PET CARE COSTS 58
- 5.2.2 STRICT REGULATORY GUIDELINES 58?
- 5.3 OPPORTUNITIES 59
- 5.3.1 RISING R&D ACTIVITIES AND PRODUCT APPROVAL FOR VETERINARY PAIN MANAGEMENT 59
- 5.3.2 RISING POPULARITY OF NON- CONVENTIONAL TREATMENT APPROACHES 60
- 5.3.3 TECHNOLOGICAL ADVANCEMENTS 60
- 5.4 CHALLENGES 61
- 5.4.1 LIMITED AVAILABILITY OF VETERINARIANS 61
- 5.4.2 RESISTANCE TO MEDICATIONS 61
- 6 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE 62
- 6.1 OVERVIEW 63
- 6.2 ANALGESICS 64
- 6.2.1 ANTI- INFLAMMATORY (NSAIDS) 64
- 6.2.1.1 CARPROFEN 65
- 6.2.1.2 MELOXICAM 65
- 6.2.1.3 PHENYLBUTAZONE 65
- 6.2.1.4 ACETAMINOPHEN 65
- 6.2.1.5 FIROCOXIB 65
- 6.2.1.6 DERACOXIB 65
- 6.2.1.7 OTHERS 66
- 6.2.2 OPIOIDS 66
- 6.2.2.1 MU AGONISTS 66
- 6.2.2.1.1 METHADONE 67
- 6.2.2.1.2 MEPERIDINE 67
- 6.2.2.1.3 MORPHINE 67
- 6.2.2.1.4 OXYMORPHONE 67
- 6.2.2.1.5 OTHERS 67
- 6.2.2.2 PARTIAL MU AGONIST 67
- 6.2.2.2.1 BUPRENORPHINE 67
- 6.2.2.2.2 OTHERS 68
- 6.2.2.3 KAPPA AGONIST MU ANTAGONIST 68
- 6.2.2.3.1 BUTORPHANOL 68
- 6.2.2.3.2 OTHERS 68
- 6.3 CORTICOSTEROIDS 69
- 6.3.1 DEXAMETHASONE 69
- 6.3.2 PREDNISOLONE 69
- 6.3.3 PREDNISONE 69
- 6.3.4 OTHERS 70
- 6.4 ALPHA 2 AGONISTS 70?
- 7 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE 71
- 7.1 OVERVIEW 72
- **7.2 BRANDED 73**
- 7.3 GENERIC 73

Scotts International. EU Vat number: PL 6772247784

- 8 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE 74
- 8.1 OVERVIEW 75
- 8.2 PRESCRIPTION BASED 76
- 8.3 OTC 76
- 9 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE 77
- 9.1 OVERVIEW 78
- 9.2 COMPANION ANIMAL 79
- 9.2.1 CANINE 80
- 9.2.2 EQUINE 80
- 9.2.3 FELINE 80
- 9.2.4 OTHERS 80
- 9.3 PRODUCTION ANIMAL 80
- 9.3.1 CATTLE 81
- 9.3.2 SWINE 81
- 9.3.3 POULTRY 81
- 9.3.4 FISH 81
- 9.3.5 OTHERS 81
- 10 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE 82
- **10.1 OVERVIEW 83**
- 10.2 CHRONIC PAIN 84
- 10.3 ACUTE PAIN 85
- 10.4 POST OPERATIVE PAIN 85
- 10.5 DENTAL PAIN 86
- 11 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE 87
- **11.1 OVERVIEW 88**
- 11.2 SOLID 89
- 11.2.1 TABLET 89
- 11.2.2 POWDER 90
- 11.2.3 OTHERS 90?
- 11.3 LIQUID 90
- 11.3.1 SOLUTION 90
- 11.3.2 SYRUP 91
- 11.3.3 SUSPENSION 91
- 11.3.4 OTHERS 91
- 11.4 SEMI SOLID 91
- 11.4.1 GEL 92
- 11.4.2 CREAM 92
- 11.4.3 OTHERS 92
- 12 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION 93
- 12.1 OVERVIEW 94
- 12.2 PARENTERAL 95
- 12.3 ORAL 96
- 12.4 TOPICAL 96
- 13 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY END USER 97
- **13.1 OVERVIEW 98**
- 13.2 VETERINARY HOSPITALS 99
- 13.3 VETERINARY CLINICS 100

## Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.4 PET SHOPS 100
- 13.5 ANIMAL FARMS 101
- 13.6 ACADEMIC & RESEARCH INSTITUTES 101
- 13.7 OTHERS 102
- 14 EUROPE VETERINARY PAIN MANAGEMENT MARKET, BY GEOGRAPHY 103
- 14.1 EUROPE 104
- 14.1.1 GERMANY 112
- 14.1.2 FRANCE 119
- 14.1.3 U K 126
- 14.1.4 ITALY 133
- 14.1.5 SPAIN 140
- 14.1.6 NETHERLANDS 147
- 14.1.7 RUSSIA 154
- 14.1.8 SWITZERLAND 161
- 14.1.9 POLAND 168
- 14.1.10 BELGIUM 175
- 14.1.11 TURKEY 182
- 14.1.12 SWEDEN 189
- 14.1.13 DENMARK 196
- 14.1.14 NORWAY 203
- 14.1.15 FINLAND 210
- 14.1.16 REST OF EUROPE 217
- 15 EUROPE VETERINARY PAIN MANAGEMENT MARKET, COMPANY LANDSCAPE 224
- 15.1 COMPANY SHARE ANALYSIS: EUROPE 224
- 16 SWOT ANALYSIS 225
- 17 COMPANY PROFILE 226
- 17.1 ZOETIS SERVICES LLC 226
- 17.1.1 COMPANY SNAPSHOT 226
- 17.1.2 COMPANY SHARE ANALYSIS 226
- 17.1.3 PRODUCT PORTFOLIO 227
- 17.1.4 RECENT DEVELOPMENTS 227
- 17.2 ELANCO 228
- 17.2.1 COMPANY SNAPSHOT 228
- 17.2.2 REVENUE ANALYSIS 228
- 17.2.3 COMPANY SHARE ANALYSIS 229
- 17.2.4 PRODUCT PORTFOLIO 229
- 17.2.5 RECENT DEVELOPMENT 229
- 17.3 MERCK & CO., INC. 230
- 17.3.1 COMPANY SNAPSHOT 230
- 17.3.2 REVENUE ANALYSIS 230
- 17.3.3 COMPANY SHARE ANALYSIS 231
- 17.3.4 PRODUCT PORTFOLIO 231
- 17.3.5 RECENT DEVELOPMENT 231
- 17.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 232
- 17.4.1 COMPANY SNAPSHOT 232
- 17.4.2 COMPANY SHARE ANALYSIS 232
- 17.4.3 PRODUCT PORTFOLIO 233

## Scotts International. EU Vat number: PL 6772247784

17.4.4 RECENT DEVELOPMENT 233

17.5 VETOQUINOL 234

17.5.1 COMPANY SNAPSHOT 234

17.5.2 REVENUE ANALYSIS 234

17.5.3 COMPANY SHARE ANALYSIS 235

17.5.4 PRODUCT PORTFOLIO 235

17.5.5 RECENT DEVELOPMENTS 235?

17.6 BIMEDA, INC. 237

17.6.1 COMPANY SNAPSHOT 237

17.6.2 PRODUCT PORTFOLIO 237

17.6.3 RECENT DEVELOPMENT 237

17.7 CEVA ANIMAL HEALTH, LLC 238

17.7.1 COMPANY SNAPSHOT 238

17.7.2 PRODUCT PORTFOLIO 238

17.7.3 RECENT DEVELOPMENT 238

17.8 CHANELLE PHARMA 239

17.8.1 COMPANY SNAPSHOT 239

17.8.2 PRODUCT PORTFOLIO 239

17.8.3 RECENT DEVELOPMENT 239

17.9 DECHRA PHARMACEUTICALS PLC 240

17.9.1 COMPANY SNAPSHOT 240

17.9.2 REVENUE ANALYSIS 240

17.9.3 PRODUCT PORTFOLIO 241

17.9.4 RECENT DEVELOPMENTS 241

17.10 DURVET ANIMAL HEALTH PRODUCTS 242

17.10.1 COMPANY SNAPSHOT 242

17.10.2 PRODUCT PORTFOLIO 242

17.10.3 RECENT DEVELOPMENT 242

17.11 INOVET (A SUBSIDIARY OF ORION GROUP) 243

17.11.1 COMPANY SNAPSHOT 243

17.11.2 PRODUCT PORTFOLIO 243

17.11.3 RECENT DEVELOPMENTS 243

17.12 NORBROOK 245

17.12.1 COMPANY SNAPSHOT 245

17.12.2 PRODUCT PORTFOLIO 245

17.12.3 RECENT DEVELOPMENT 245

17.13 VIRBAC 246

17.13.1 COMPANY SNAPSHOT 246

17.13.2 REVENUE ANALYSIS 246

17.13.3 PRODUCT PORTFOLIO 247

17.13.4 RECENT DEVELOPMENT 247

18 OUESTIONNAIRE 248

19 RELATED REPORTS 252



☐ - Print this form

To place an Order with Scotts International:

# **Europe Veterinary Pain Management Market - Industry Trends and Forecast to 2032**

Market Report | 2023-09-01 | 252 pages | Data Bridge Market Research

<ul><li>Complete the re</li></ul>	levant blank fields and sign			
<ul><li>Send as a scann</li></ul>	ed email to support@scotts-intern	ational.com		
ORDER FORM:				
Select license	License			Price
	Single User License			\$3500.00
	Corporate Users License			\$4200.00
			VAT	
			Total	
** VAT will be added a	ant license option. For any questions pl t 23% for Polish based companies, indi	viduals and EU based cor		
Email*		Phone*		
First Name*		Last Name*		
Job title*				
Company Name*		EU Vat / Tax ID / N	IP number*	
Address*		City*		
Zip Code*		Country*		
		Date	2025-05-11	
		Signature		

Scotts International. EU Vat number: PL 6772247784